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To elucidate the role of (1®®®®® 3)-bbbbb -D-glucan in pulm onary
aspergillom a,  serum   concentrations  of  (1®®®®® 3)-bbbbb -D-
glucan  were  m easured  repeatedly  for  as  long  as  10
m onths in eight patients. In four patients with inactive
disease, concentrations of (1®®®®® 3)-bbbbb -D-glucan were in the
norm al range.  The concentrations of (1®®®®® 3)-bbbbb -D-glucan
increased in two patients, although the disease was in-
active.  This increase m ight show the earliest stage of
the invasive process of the disease. In two other patients
with active disease, (1®®®®® 3)-bbbbb -D-glucan increased. Other
param eters, such as galactom annan, im munodiffusion
and a radio-allergosorbent test, as well as inflam ma-
tory  m arkers  suc h  as  C-reactiv e  protein  and  the
leukocyte count, did not show any consistent tendency
in regard to the activity of the disease. Thus, a (1®®®®® 3)-
bbbbb -D-glucan assay m ay add valuable data for evaluating
the disease activity and understanding the disease proc-
ess of pulm onary aspergilloma.
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Introduction
In a previous study, w e measured serum (1 ® 3)-b -D-
glucan in patients with pulmonary aspergillosis and
found that (1® 3)-b -D-glucan increased in some cas-
es of pulmonary aspergilloma,  in which the fungus
was considered not to have invaded the surrounding
tissue or blood stream  [1].
In the present study, to elucidate the role of (1® 3)-
b -D-glucan  in  pulm onary  aspergillom a,  serum   con-
centrations of (1® 3)-b -D-glucan were measured re-
peatedly for as long as 10 months in eight patients.
Materials and methods
Subjects
E ight  patients  with  pulm onary  aspergillom a  were
enrolled in the study (Table 1). Of the eight patients,
the disease was inactive in six. In patient 7,  hemo-
sputum was frequently observed throughout the fol-
low-up period, and in patient 8, the fungus ball stead-
ily increased in size.  The disease was judged to be
active in these two patients. Itraconazole (ITCZ) at
100±200 mg/day,  was  adm inistered  throughout  the
follow-up period to all but patient 7.
Clinical evaluation
The patient’ s physical  condition,  a chest  X-ray and
blood tests (leukocyte count, C-reactive protein) w ere
examined once a month in each patient  to evaluate
the activity of the disease.
Measurement of (1® 3)-b -D-glucan
The concentrations of (1® 3)-b -D-glucan were m eas-
ured following the method described by Obayashi et
al. [2,3] and Morita et al. [4]. W ith this method, the
cut-off value for (1® 3)-b -D-glucan was set at 20 pg/
ml [5].
Measurement of other Aspergillus-related
substances
Anti-Aspergillus im munoglobulin (Ig)E antibody was
measured by a radio-allergosorbent test (>0.34 U/ml
was  positive).  The  presence  of  Aspergillus-specific
antibodies in sera was examined by immunodiffusion.
The Aspergillus-specific cell-surface component ga-
lactomannan was assayed with Pastorex Asperg illus
(Sanofi  Diagnostics  Pasteur,  Genk,  Belgium).  T he
sensitivity  of  the  test  was  15 ng/ml of galactoman-
nan [6].
Results and discussion
On the basis of the concentration of (1® 3)-b -D-glu-
can and the clinical activity of pulm onary aspergillo-
m a,  the  patients  were  classified  into  three  groups:
group 1, normal (1® 3)-b -D-glucan with inactive dis-
ease; group 2, increased (1® 3)-b -D-glucan with in-
active disease; and group 3, increased (1® 3)-b -D-glu-
can with active disease.
Group 1 consisted of patients 1±4 (Table 2). In this
group,  the  values  of  galactomannan,  immunodiffu-
sion, radio-allergosorbent test and C-reactive protein
were variable in each patient, and there were no sig-
nificant correlations among these values.
Patients 5 and 6 were classified in group 2 (Table
3). In this group, (1® 3)-b -D-glucan exceeded 20 pg/
ml. However, there were no obvious signs of active
disease.  Other  parameters,  such  as  galactomannan,
immunodiffusion,  the  radio-allergosorbent  test  and286         Mediators of Inflammation ￿ Vol 6 ￿ 1997
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Table 1. Details of all study patients
Age Initiation of
Patient (years) Sex Diagnosis Treatment treatment
1 60 Male Aspergilloma ITCZ at 150 mg/day 21 Nov 1995
2 78 Male Aspergilloma ITCZ at 200 mg/day 14 Apr 1995
3 78 Male Aspergilloma ITCZ at 100 mg/day 11 Jan 1994
4 67 Female Aspergilloma ITCZ at 150 mg/day 05 Dec 1994
5 67 Male Aspergilloma ITCZ at 200 mg/day 28 Feb 1995
6 67 Male Aspergilloma ITCZ at 100 mg/day 28 Sep 1994
7 79 Male Aspergilloma
8 83 Male Aspergilloma ITCZ at 150 mg/day 23 Aug 1995
ITCZ, itraconazole.
Table 2. Follow-up study of group 1
Leukocytes CRP RAST Immuno- Galacto- Glucan
(count/m l) (mg/dl) (U/ml) diffusion mannan (pg/ml)
Patient 1
08 Nov 1995 7400 8.7 4.2 + – 13.4
11 Nov 1995 6900 4.2 ND ND ND 4.9
04 Dec 1995 6600 5.0 4.12 + – 6.3
22 Jan 1996 8300 4.9 3.42 + – 11.7
19 Feb 1996 6400 5.1 3.99 + – 13.6
18 Mar 1996 7500 5.0 2.96 + – 13.6
Patient 2
13 Jun 1995 4700 0.8 0.37 + – 9.0
07 Aug 1995 4900 0.9 <0.34 + – 19.3
04 Sep 1995 4500 1.1 <0.34 + – 15.3
03 Oct 1995 5200 1.1 0.37 + – 5.2
30 Oct 1995 4800 0.6 0.46 + – 14.3
27 Nov 1995 5400 0.4 0.69 + – 4.5
26 Dec 1995 7700 0.4 0.50 + – 11.2
22 Jan 1996 5500 0.9 0.49 + – 12.0
19 Feb 1996 6800 0.6 0.53 + – 14.7
18 Mar 1996 5800 1.4 0.56 + – 3.0
Patient 3
16 May 1995 7000 0.4 1.46 + ND 6.8
20 Jun 1995 5300 0.6 1.54 ND – 5.6
11 Jul 1995 6500 1.0 1.21 ND – 0.0
08 Aug 1995 5600 0.7 1.28 + + 1.3
12 Sep 1995 6600 0.5 1.37 ND – 0.8
20 Oct 1995 5900 0.4 1.58 ND – 1.6
14 Nov 1995 7100 0.6 2.16 + – 4.2
12 Dec 1995 5500 1.2 2.22 ND – 6.0
16 Jan 1996 5300 0.4 1.85 ND – 19.2
13 Feb 1996 5400 0.9 2.06 + + ND
12 Mar 1996 5300 0.7 1.69 ND – 15.7
Patient 4
22 May 1995 6300 0.0 0.50 + + 12.2
19 Jun 1995 7100 0.1 0.48 + + 6.1
17 Jul 1995 7200 0.0 0.54 + + 12.0
14 Aug 1995 7100 0.0 ND ND ND 8.8
25 Sep 1995 7100 0.0 0.43 + + 4.6
23 Oct 1995 6900 0.1 0.35 + +/– 7.4
20 Nov 1995 8700 1.2 0.82 + + 5.8
18 Dec 1995 6400 0.2 0.77 + + 14.9
08 Jan 1996 5700 0.1 0.79 + + 6.5
11 Mar 1996 6100 0.1 0.69 + + 6.7
CRP , C-reactive protein; RAST, radio-allergosorbent test; ND, not determined.
C-reactive protein, were dissociated from each other.
Thus the reason why there appeared to be no obvious
signs of disease m ay be that Aspergillus had just start-
ed to invade the surrounding tissue and had not pro-
gressed  enough  to  be  detectable  by  conventional
methods. How ever, further follow-up studies are re-
quired to verify this hypothesis.
Group 3 comprised patients 7 and 8 (Table 4). Pa-
tient 7 had complained of frequent hemosputum since
1979, w hen he was diagnosed as suffering from  pul-
monary aspergillom a. In this case, values of (1® 3)-
b -D-glucan and radio-allergosorbent test were elevat-
ed.  Galactom annan  was  seldom  detected,  however.
In patient 8,  the fungus ball  showed steady growth
until 1995, when the patient w as enrolled in the study.
In this case, to elucidate the day-to-day variation, the
concentrations of (1® 3)-b -D-glucan were measured
daily for 2 weeks. The size of the fungus ball remainedPatients with pulmonary aspergilloma
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Table 3. Follow-up study of Group 2
Leukocytes CRP RAST Immuno- Galacto- Glucan
(count/m l) (mg/dl) (U/ml) diffusion mannan (pg/ml)
Patient 5
22 Jun 1995 5800 1.6 <0.34 + – 7.2
17 Aug 1995 4900 3.1 <0.34 + – 18.8
14 Sep 1995 ND ND <0.34 + – 22.5
09 Nov 1995 7300 2.6 ND ND ND 22.4
07 Dec 1995 6000 2.9 ND + – 17.1
08 Feb 1996 6700 2.7 ND + – 21.3
27 Feb 1996 7400 3.0 ND ND ND ND
14 Mar 1996 ND ND ND ND ND 21.6
Patient 6
18 May 1995 9500 12.7 1.77 – – 21.0
15 Jun 1995 8100 3.7 1.44 ND – 13.8
14 Jul 1995 9300 3.6 1.45 – – 10.8
25 Aug 1995 7700 5.5 0.89 ND – 26.0
22 Sep 1995 6500 3.8 1.16 ND – 27.4
20 Oct 1995 9100 3.0 1.60 – – 28.7
24 Nov 1995 7800 2.7 1.70 ND – 37.3
22 Dec 1995 8200 5.0 2.10 ND – 26.8
19 Jan 1996 5000 2.5 1.91 – – 22.5
16 Feb 1996 4600 6.4 2.13 ND – 14.2
15 Mar 1996 7600 4.2 1.85 ND – 24.6
CRP , C-reactive protein; RAST, radio-allergosorbent test; ND, not determined.
Table 4. Follow-up study of Group 3
Leukocytes CRP RAST Immuno- Galacto- Glucan
(count/m l) (mg/dl) (U/ml) diffusion mannan (pg/ml)
Patient 7
26 May 1995 5500 2.6 10.12 ND – 60.1
30 Jun 1995 6200 2.4 9.38 ND – 59.3
28 Jun 1995 6500 3.0 11.20 + + 55.0
25 Aug 1995 6900 3.1 12.95 ND + 52.1
22 Sep 1995 5500 2.4 12.37 ND – 54.1
20 Oct 1995 6200 4.3 12.71 + – 56.9
14 Nov 1995 5500 3.5 20.92 ND – 41.8
19 Dec 1995 6700 3.3 18.45 ND – 33.6
16 Jan 1996 6500 3.1 15.81 ND – 24.6
20 Feb 1996 10 900 2.4 21.60 ND – 47.6
Patient 8
31 Jul 1995 5800 0.2 <0.34 – – ND
23 Aug 1995 ND ND ND ND ND 42.0
24 Aug 1995 ND ND ND ND ND 28.2
25 Aug 1995 ND ND ND ND ND 32.4
28 Aug 1995 ND ND ND ND ND 32.4
29 Aug 1995 ND ND ND ND ND 35.1
30 Aug 1995 5200 0.1 ND ND ND 36.0
31 Aug 1995 ND ND ND ND ND 34.5
04 Sep 1995 ND ND ND ND ND 16.1
05 Sep 1995 ND ND ND ND ND 11.1
07 Sep 1995 5100 0.2 ND ND ND 11.0
CRP , C-reactive protein; RAST, radio-allergosorbent test; ND, not determined.
unchanged and (1® 3)-b -D-glucan values were nor-
malized during the period.
In  contrast  to  the  prevalent  notion,  increased
(1® 3)-b -D-glucan values in this group m ight imply
that Aspergillus in the lesion of aspergilloma can in-
vade  surrounding  tissue  and/or  the  bloodstream ,
though  the  invasion  is  radiologically  undetectable.
The  prom pt  decline  in  serum  (1® 3)-b -D-glucan  in
patient 8 m ay support this concept.
In summary, the data presented here suggest that
the (1® 3)-b -D-glucan assay may add valuable data
for evaluating the disease activity as well as for un-
derstanding  the  disease  process  of  pulm onary  as-
pergillom a.
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